Fundraising FoxNeurovance
Cambridge, US · Founded 2011 · Delaware corporation · 1 known investors
Find your way into Neurovance
Sign up to see every warm intro you have to Neurovance
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Neurovance team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
GB
Gregg BeloffActing Chief Financial Officer
WT
William T. PappafotopoulosVice President, Finance and Administration
JB
Jeffrey BaileyExecutive Chairman
AA
Anthony A. McKinneyChief Development Officer
FP
Franklin P. BymasterExecutive
TA
Thomas A. SheaExecutive
PT
Pierre TranExecutive
Board
CM
Campbell MurrayBoard director
DO
Daniel OmsteadBoard director
BS
Brigitte SmithBoard director
PW
Paul WeissBoard director
AB
Andrew BakerBoard director
Investors · 1
Novartis Venture FundreportedBasel · $5M – $25M
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$54.7M disclosed across 5 rounds · 2012–2016
▶$554.3KraisedJan 2017 · 1 investors · BiotechnologyRule 506(b)
▶$554.3KraisedJan 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Timothy J. BarberichDirector
- Anthony A. McKinneyExecutive Officer
- Albert L. SokolExecutive Officer
- Paul WeissDirector
- Brigitte SmithDirector
- Jeffrey BaileyExecutive Officer, Director
- Daniel OmsteadDirector
- Campbell MurrayDirector
- William T. PappafotopoulosExecutive Officer
- Brian GoffExecutive Officer, Director
- Gregg BeloffExecutive Officer
- Offering amount
- $554.3K
- Amount sold
- $554.3K
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.5MraisedDec 2016 · 7 investors · BiotechnologyRule 506(b)
▶$7.5MraisedDec 2016 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Albert L. SokolExecutive Officer
- Campbell MurrayDirector
- Daniel OmsteadDirector
- Timothy J. BarberichDirector
- Gregg BeloffExecutive Officer
- Brigitte SmithDirector
- William T. PappafotopoulosExecutive Officer
- Paul WeissDirector
- Jeffrey BaileyExecutive Officer, Director
- Anthony A. McKinneyExecutive Officer
- Offering amount
- $16M
- Amount sold
- $7.5M
- First sale
- Feb 2016
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$26.5MraisedJun 2015 · 7 investors · BiotechnologyRule 506(b)
▶$26.5MraisedJun 2015 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William T. PappafotopoulosExecutive Officer
- Albert L. SokolExecutive Officer
- Brigitte RobertsonExecutive Officer
- Campbell MurrayDirector
- Timothy J. BarberichDirector
- Daniel OmsteadDirector
- Franklin P. BymasterExecutive Officer
- Anthony A. McKinneyExecutive Officer, Director
- Brigitte SmithDirector
- Paul WeissDirector
- Offering amount
- $26.5M
- Amount sold
- $26.5M
- Minimum investment
- $16.3K
- First sale
- Oct 2012
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$20MraisedMar 2015 · 7 investors · Other TechnologyRule 506(b)
▶$20MraisedMar 2015 · 7 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Campbell MurrayDirector
- Daniel OmsteadDirector
- Anthony A. McKinneyExecutive Officer, Director
- William T. PappafotopoulosExecutive Officer
- TImothy J. BarberichDirector
- Albert L. SokolExecutive Officer
- Franklin P. BymasterExecutive Officer
- Walter PiskorskiExecutive Officer
- Brigitte SmithDirector
- Brigitte RobertsonExecutive Officer
- Paul WeissDirector
- Offering amount
- $20M
- Amount sold
- $20M
- Minimum investment
- $16.3K
- First sale
- Oct 2012
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
▶$163.5KraisedMar 2012 · 6 investors · Other TechnologyRule 506(b)
▶$163.5KraisedMar 2012 · 6 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Timothy J. BarberichDirector
- Paul WeissDirector
- Frank GentileDirector
- Franklin P. BymasterExecutive Officer
- Thomas A. SheaExecutive Officer
- Campbell MurrayDirector
- Anthony A. McKinneyExecutive Officer, Director
- Pierre TranExecutive Officer
- Andrew BakerDirector
- Offering amount
- $478.1K
- Amount sold
- $163.5K
- Minimum investment
- $2.5K
- First sale
- Mar 2012
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are Neurovance's investors?
- Neurovance's investors include Novartis Venture Fund.
- How much funding has Neurovance raised?
- Neurovance has disclosed $54.7M raised across 5 rounds.
- Where is Neurovance headquartered?
- Neurovance is headquartered in Cambridge, US.